Literature DB >> 10527802

Preclinical testing of neuroprotective neurotrophic factors in a model of chronic motor neuron degeneration.

A M Corse1, M M Bilak, S R Bilak, M Lehar, J D Rothstein, R W Kuncl.   

Abstract

Many neurotrophic factors have been shown to enhance survival of embryonic motor neurons or affect their response to injury. Few studies have investigated the potential effects of neurotrophic factors on more mature motor neurons that might be relevant for neurodegenerative diseases. Using organotypic spinal cord cultures from postnatal rats, we have demonstrated that insulin-like growth factor-I (IGF-I) and glial-derived neurotrophic factor (GDNF) significantly increase choline acetyltransferase (ChAT) activity, but brain-derived neurotrophic factor (BDNF), neurotrophin-4 (NT-4/5), and neurotrophin-3 (NT-3) do not. Surprisingly, ciliary neurotrophic factor (CNTF) actually reduces ChAT activity compared to age-matched control cultures. Neurotrophic factors have also been shown to alter the sensitivity of some neurons to glutamate neurotoxicity, a postulated mechanism of injury in the neurodegenerative disease, amyotrophic lateral sclerosis (ALS). Incubation of organotypic spinal cord cultures in the presence of the glutamate transport inhibitor threo-hydroxyaspartate (THA) reproducibly causes death of motor neurons which is glutamate-mediated. In this model of motor neuron degeneration, IGF-I, GDNF, and NT-4/5 are potently neuroprotective, but BDNF, CNTF, and NT-3 are not. The organotypic glutamate toxicity model appears to be the best preclinical predictor to date of success in human clinical trials in ALS. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10527802     DOI: 10.1006/nbdi.1999.0253

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  22 in total

1.  Protective effect of a new hypothalamic peptide against cobra venom and trauma-induced neuronal injury.

Authors:  A A Galoyan; J S Sarkissian; T K Kipriyan; E J Sarkissian; E A Chavushyan; R M Sulkhanyan; I B Meliksetyan; S S Abrahamyan; Z A Avetisyan; N A Otieva
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

Review 2.  Organotypic Spinal Cord Culture: a Proper Platform for the Functional Screening.

Authors:  Sareh Pandamooz; Mohammad Nabiuni; Jaleel Miyan; Abolhassan Ahmadiani; Leila Dargahi
Journal:  Mol Neurobiol       Date:  2015-08-27       Impact factor: 5.590

Review 3.  Motor neuron trophic factors: therapeutic use in ALS?

Authors:  Thomas W Gould; Ronald W Oppenheim
Journal:  Brain Res Rev       Date:  2010-10-21

4.  Drug treatment for spinal muscular atrophy types II and III.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2020-01-06

5.  Effect of the PARP-1 inhibitor PJ 34 on excitotoxic damage evoked by kainate on rat spinal cord organotypic slices.

Authors:  Graciela L Mazzone; Andrea Nistri
Journal:  Cell Mol Neurobiol       Date:  2010-12-29       Impact factor: 5.046

6.  Clinical testing and spinal cord removal in a mouse model for amyotrophic lateral sclerosis (ALS).

Authors:  René Günther; Martin Suhr; Jan C Koch; Mathias Bähr; Paul Lingor; Lars Tönges
Journal:  J Vis Exp       Date:  2012-03-17       Impact factor: 1.355

Review 7.  Glutamate and neurotrophic factors in neuronal plasticity and disease.

Authors:  Mark P Mattson
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

8.  Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS.

Authors:  Angelo C Lepore; Christine Haenggeli; Mehdi Gasmi; Kathie M Bishop; Raymond T Bartus; Nicholas J Maragakis; Jeffrey D Rothstein
Journal:  Brain Res       Date:  2007-09-22       Impact factor: 3.252

9.  Brain slices as models for neurodegenerative disease and screening platforms to identify novel therapeutics.

Authors:  Seongeun Cho; Andrew Wood; Mark R Bowlby
Journal:  Curr Neuropharmacol       Date:  2007-03       Impact factor: 7.363

10.  Experimental models for the study of neurodegeneration in amyotrophic lateral sclerosis.

Authors:  Luis B Tovar-Y-Romo; Luz Diana Santa-Cruz; Ricardo Tapia
Journal:  Mol Neurodegener       Date:  2009-07-20       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.